When glioblastoma (GBM) comes back after initial treatment, deciding whether radiation can be used again - and what type - is one of the hardest calls in neuro-oncology. Most families reach this point already exhausted, and the choices on paper can feel like too much. Three main methods can re-treat recurrent GBM: hypofractionated stereotactic radiotherapy (HFSRT), stereotactic radiosurgery (SRS), and brachytherapy. Each works differently, uses a different schedule, has different eligibility rules, and carries different risks. Below is what the research shows about how they compare, so you can ask your oncology team the right questions.
What is re-irradiation for recurrent glioblastoma?
Re-irradiation means giving a second round of radiation to brain tissue that already received radiation - usually 60 Gy over six weeks as part of the Stupp protocol, the standard first treatment that combines radiation and chemotherapy. At the time of recurrence, the goal is to aim radiation at the returning tumor while keeping the extra dose to surrounding healthy tissue as low as safely possible. Because the brain can only handle so much radiation without permanent damage, re-irradiation must be delivered with great precision and careful accounting of total dose.
Re-irradiation is just one of several salvage strategies available at recurrence. Our guide to recurrent GBM salvage options covers where it fits alongside reoperation, systemic therapy, and clinical trials.
Does re-irradiation improve survival for recurrent GBM?
Research suggests it can extend survival for carefully selected patients, though it is not curative. An analysis of data from more than 300 GBM patients found that re-irradiation was associated with an increase in six-month progression-free survival from 28% to 39% and in one-year overall survival from 18% to 48%, compared to patients who did not receive re-irradiation - without additional chemotherapy. (Re-irradiation alternatives for recurrent high-grade glioma, PMC)
A separate study found that patients who had re-irradiation lived 24.6 months from initial GBM diagnosis, compared to 12.6 months in those who did not. (Re-Irradiation and Its Contribution to Good Prognosis in Recurrent GBM, PMC) These numbers come from highly selected patient groups - they show what happened to patients who met strict criteria, not what happens to the average recurrent GBM patient. But enough studies show similar results that re-irradiation is now used as a salvage option at specialized centers.
Who qualifies for re-irradiation?
Patient selection is the most critical step in re-irradiation planning. Studies show that doctors usually require the following: (PMC)
- Karnofsky Performance Score (KPS) above 60 - a 0-to-100 scale measuring activity level, where 100 means fully active and 0 means unable to care for oneself
- Recurrent tumor no larger than 40 mm across
- At least six months since the original radiation treatment
- Cancer coming back in one area, not spread throughout the brain
Doctors also consider where the tumor sits relative to critical brain structures like the brainstem and eye nerves, how much total radiation the brain has already received, and whether surgery is planned at the same time. Each case is unique. There is no formula that can replace a specialist's judgment here.
How do HFSRT, SRS, and brachytherapy compare for recurrent glioblastoma?
| Factor | Hypofractionated Stereotactic Radiation (HFSRT) | Stereotactic Radiosurgery (SRS) | Brachytherapy |
|---|---|---|---|
| Sessions (fractions) | 3-5 sessions over 1-2 weeks | 1 session (single outpatient visit) | Continuous delivery over days to weeks after surgical placement |
| Typical tumor size | Up to about 5 cm | Works best for tumors smaller than 3 cm | Up to about 4 cm (must be surgically accessible) |
| Invasiveness | Non-invasive (external beam) | Non-invasive (external beam) | Surgical procedure required for device placement |
| Best suited when | Medium-sized tumor that needs quick treatment | Small, well-defined lesion; good performance status | Reoperation is already planned at recurrence |
| Key advantage | Precise targeting of dose; fewer visits than standard radiation; widely available | Single outpatient session; highly precise | High dose right at the tumor with very little dose outside |
| Main risk | Dead brain tissue from repeated radiation; risk to already-treated area | Does not work for large tumors; risk of dead brain tissue from one large dose | Surgery risks; only for patients strong enough for another operation |
Sources: PMC5038913; PMC6200913; PMC1871978
There is no one best method for everyone. HFSRT is most commonly used at specialized centers, mainly because it works for different sized tumors and does not require surgery. SRS works well for small, clear tumors and is done in one session - important for patients who travel from far away. Brachytherapy delivers the most focused radiation right at the tumor, but it is only available at some centers and only for patients strong enough for surgery.
Hypofractionated stereotactic radiotherapy (HFSRT) - how it works
HFSRT combines precise targeting with a shorter treatment schedule. Regular radiation treatment gives 30 daily doses over six weeks. HFSRT does the same in three to five sessions - with each one giving a higher dose. Precise imaging guides the radiation beam tightly around the tumor's shape, so less healthy brain tissue gets significant radiation.
One hospital study found that patients lived a median of 9.5 months after re-irradiation, and most were treated as outpatients. HFSRT works for tumors too large for single-session SRS and needs no surgery. This is why it is used most often at cancer centers. For patients dealing with fatigue and memory problems, or those traveling far, one to two weeks of treatment is much easier than six weeks.
Stereotactic radiosurgery (SRS) for recurrent glioblastoma - how it works
Despite its name, SRS does not involve surgery or cuts. SRS delivers one big, highly focused dose of radiation in a single session using equipment like Gamma Knife, CyberKnife, or a special linear accelerator. This one big dose works because tumor cells have little time to repair damage between sessions - different from regular radiation that spreads treatment over many days.
SRS works best for small tumors under 3 cm with clear edges and good distance from key brain areas. Studies show patients live a median of six to ten months after SRS for recurrent GBM. (Re-irradiation for malignant glioma: patient selection and treatment parameters, PMC)
For patients thinking about traveling, SRS is practical: you get all treatment in one visit. The same questions apply when choosing a high-precision radiation center anywhere.
Brachytherapy for recurrent glioblastoma - how it works
Brachytherapy delivers radiation from inside the tumor cavity rather than from an external beam. Two forms are in use for recurrent GBM at specialized centers:
- Interstitial seed implants: Radioactive iodine seeds are placed directly into the tumor or cavity during surgery. They give off radiation continuously for weeks until they run out. A second surgery is not needed to remove them.
- Balloon brachytherapy (GliaSite system): At surgery, doctors place a balloon tube into the cavity where the tumor was. A few days later, they fill the balloon with a radioactive liquid that delivers radiation for several days. Then they remove the tube in a simple outpatient visit.
One study found patients with a KPS of 70 or above lived 9.3 months on average after balloon brachytherapy, compared to 3.1 months for those with KPS below 70. (Permanent iodine-125 brachytherapy in progressive or recurrent GBM, PMC) This big difference shows how much the patient's starting health matters, especially for a technique that requires surgery.
The main advantage of brachytherapy is where the radiation comes from. Since radiation comes from inside the cavity, most of it stays right there, protecting brain tissue that already got radiation. The main problem is that not every hospital can do this. It only works for patients strong enough for another surgery.
Radiation necrosis: the risk that shapes every re-irradiation decision
Radiation necrosis is the biggest risk of re-irradiation. It happens when brain tissue that already got radiation is damaged again by the second treatment. This creates dead or damaged tissue that can cause swelling and neurological problems. On MRI, radiation necrosis looks almost like the tumor came back, which can confuse doctors and make treatment decisions harder.
A study in the Journal of Neuro-Oncology found that a total radiation dose above 120-130 Gy (calculated as if given in standard daily fractions) significantly increased the risk of radiation necrosis. (Re-irradiation for recurrent high-grade glioma: prognostic factors for survival and predictors of radiation necrosis, PubMed) Doctors use this threshold as a key calculation when planning re-treatment.
Doctors try several things to reduce necrosis risk: waiting longer between radiation treatments, limiting how much tissue gets re-treated, and sometimes adding bevacizumab, a drug that protects blood vessels. When MRI results after re-irradiation are unclear, telling necrosis from real tumor growth may need special MRI scans or PET scans. See this article on pseudoprogression versus true tumor recurrence in glioblastoma for more on these imaging challenges.
How is the right approach chosen?
Doctors choose between HFSRT, SRS, and brachytherapy based on five things: tumor size and location, how long ago the first radiation was, total radiation dose the brain already got, whether surgery is planned, and how healthy and strong the patient is. Also, not every hospital has all three methods or enough experience with them.
NCCN guidelines do not name one best method for recurrent GBM re-irradiation. That is because no studies directly compare these three methods. Different studies use different kinds of patients, so they are hard to compare. Because there is no clear winner, getting a specialist opinion really matters.
If your team suggests one approach but the reasons are not clear to you, or if you are not sure the center has enough experience with that method, getting a second opinion before starting is smart. You can get a remote second opinion from Art of Healing Cancer to have your scans and treatment history reviewed by a specialist team without traveling.
When to talk to your doctor
Talk to your doctor about re-irradiation if: the tumor coming back is shown on imaging, not just from symptoms; your KPS is above 60; it has been at least six months since your first radiation; and the tumor came back in one spot on MRI. Ask how much total radiation your brain already got, which method the team suggests and why it works for your tumor, what the necrosis risk is for their plan, and if bevacizumab is part of the plan. If re-irradiation is not being offered, ask why and if the answer would change with a different method or center.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.